Relmada Therapeutics, Inc. (NASDAQ: RLMD) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
5.30
-0.01-0.19%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 6.18% | Shs Outstand | 104.89M | Perf Week | 2.51% |
| Market Cap | 556.97M | Forward P/E | - | EPS next Y | -0.96 | Insider Trans | - | Shs Float | 90.42M | Perf Month | -16.90% |
| Enterprise Value | 547.19M | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 14.37% | Perf Quarter | -29.39% |
| Income | -71.29M | P/S | 0.00 | EPS this Y | - | Inst Trans | - | Short Ratio | 8.08 | Perf Half Y | 35.81% |
| Sales | 0.00 | P/B | 2.10 | EPS next Y | -16.73% | ROA | -25.02% | Short Interest | 12.99M | Perf YTD | 9.94% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -71.22% | 52W High | 7.99 -33.63% | Perf Year | 729.56% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -27.12% | 52W Low | 0.55 865.45% | Perf 3Y | 732.94% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 5.62% 6.49% | Perf 5Y | 2.51% |
| Dividend TTM | - | EV/Sales | 0.00 | EPS Y/Y TTM | 58.87% | Oper. Margin | 0.00% | ATR (14) | 0.39 | Perf 10Y | 223.78% |
| Dividend Ex-Date | - | Quick Ratio | 18.26 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 39.29 | Recom | 2.50 |
| Dividend Gr. 3/5Y | - | Current Ratio | 18.26 | EPS Q/Q | 62.07% | SMA20 | -6.47% | Beta | 0.31 | Target Price | 11.00 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | - | SMA50 | -15.28% | Rel Volume | 1.02 | Prev Close | 5.31 |
| Employees | 17 | LT Debt/Eq | -0.50 | Earnings | Aug 06 | SMA200 | 1.83% | Avg Volume | 1.68M | Price | 5.30 |
| IPO Date | Jun 20, 2014 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -9.81% - | Net Debt/EBITDA | 0.17 | Volume | 1,717,939 | Change | -0.19% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jun-18-26 | Initiated | H.C | Buy | $12 |
| Mar-13-26 | Reiterated | Mizuho Securities | Outperform | $10 |
| Jan-23-26 | Upgrade | Leerink Partners | Market Perform → Outperform | $8.00 |
| Dec-22-25 | Initiated | Jefferies | Buy | $8.00 → $9.00 |
| Nov-19-25 | Upgrade | Mizuho | Neutral → Outperform | |
| Dec-05-24 | Downgrade | Mizuho | Outperform → Neutral | |
| Dec-04-24 | Downgrade | Leerink Partners | Outperform → Market Perform | |
| Jun-05-24 | Downgrade | Goldman Sachs | Neutral → Sell | $2.00 |
| Oct-14-22 | Downgrade | Goldman Sachs | Buy → Neutral | |
| Oct-14-22 | Downgrade | Guggenheim | Buy → Neutral |
Latest News
Jul-29-26
Jul-29-2603:45AM
Jul-28-26
Jul-28-2608:30AM
Jul-19-26
Jul-19-2604:03AM
Jul-16-26
Jul-16-2607:05AM
Jun-29-26
07:00AM
Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexesglobenewswire.com
Jun-19-26
Jun-19-2610:47AM
Jun-18-26
07:45AM
Company
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 6/30/2019 | FY 2017 6/30/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Selling, General and Administrative Excl. Other | 0 | 38 | 49 | 48 | 35 | 25 | 7 | 6 | 4 | |
| Research and Development | 1 | 46 | 55 | 113 | 91 | 36 | 8 | 7 | 3 | |
| Other Operating Expense | 58 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Operating Income | -59 | -84 | -104 | -161 | -126 | -61 | -15 | -13 | -7 | |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 2 | 4 | 5 | 4 | 0 | 1 | 0 | -5 | -1 | |
| Net Income Before Taxes | -57 | -80 | -99 | -157 | -126 | -59 | -15 | -17 | -9 | |
| Income Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | |
| Consolidated Net Income | -57 | -80 | -99 | -157 | -126 | -59 | -15 | -17 | -9 | |
| Net Income From Continuing Operations | -57 | -80 | -99 | -157 | -126 | -59 | -15 | -17 | -9 | |
| Net Income | -57 | -80 | -99 | -157 | -126 | -59 | -15 | -17 | -9 | |
| EPS (Recurring) | -1.45 | -2.65 | -3.28 | -5.30 | -7.16 | -3.81 | -1.63 | -2.74 | -2.86 | |
| EPS (Basic, Before Extraordinaries) | -1.45 | -2.65 | -3.28 | -5.30 | -7.16 | -3.81 | -1.63 | -2.74 | -2.86 | |
| EPS (Diluted) | -1.45 | -2.65 | -3.28 | -5.30 | -7.16 | -3.81 | -1.63 | -2.74 | -2.86 | |
| EBITDA | -57 | -80 | 5 | -157 | -126 | -59 | -15 | -17 | -7 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 39 | 30 | 30 | 30 | 18 | 16 | 9 | 6 | 3 | |
| Market Capitalization | 188 | 16 | 31 | 26 | 81 | 103 | 70 | 9 | 2 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| TRAVERSA SERGIO | Chief Executive Officer | Dec 15 '25 | Buy | 4.12 | 27,500 | 113,300 | 1,300,000 | Dec 16 |
| Shenouda Maged | Chief Financial Officer | Dec 15 '25 | Buy | 4.12 | 11,665 | 48,060 | 800,000 | Dec 16 |
| Shenouda Maged | Chief Financial Officer | Nov 05 '25 | Buy | 2.20 | 500,000 | 1,100,000 | 788,335 | Nov 06 |
| Ence Chuck | CAO and COO | Nov 05 '25 | Buy | 2.20 | 136,000 | 299,200 | 403,931 | Nov 06 |
| TRAVERSA SERGIO | Chief Executive Officer | Nov 05 '25 | Buy | 2.20 | 272,500 | 599,500 | 1,272,500 | Nov 06 |
| Kelly Paul Edward | Chief Operating Officer | Nov 05 '25 | Buy | 2.20 | 90,000 | 198,000 | 502,295 | Nov 06 |
| TRAVERSA SERGIO | Chief Executive Officer | Aug 28 '25 | Buy | 0.74 | 55,976 | 41,422 | 1,000,000 | Aug 28 |
| TRAVERSA SERGIO | Chief Executive Officer | Aug 27 '25 | Buy | 0.67 | 129,455 | 86,735 | 944,024 | Aug 28 |
| TRAVERSA SERGIO | Chief Executive Officer | Aug 26 '25 | Buy | 0.62 | 80,545 | 49,938 | 814,569 | Aug 28 |
| TRAVERSA SERGIO | Chief Executive Officer | May 20 '25 | Buy | 0.56 | 147,686 | 82,246 | 734,024 | May 20 |
| Shenouda Maged | Chief Financial Officer | May 20 '25 | Buy | 0.52 | 60,000 | 31,422 | 288,335 | May 20 |
| Shenouda Maged | Chief Financial Officer | May 19 '25 | Buy | 0.49 | 90,000 | 43,686 | 228,335 | May 20 |
| TRAVERSA SERGIO | Chief Executive Officer | May 19 '25 | Buy | 0.50 | 30,000 | 14,994 | 586,338 | May 20 |
| TRAVERSA SERGIO | Chief Executive Officer | May 16 '25 | Buy | 0.45 | 172,314 | 77,472 | 556,338 | May 20 |
| Shenouda Maged | Chief Financial Officer | May 16 '25 | Buy | 0.44 | 50,000 | 22,100 | 138,335 | May 20 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.